XERS SEC Filings, Earnings & Splits

Xeris Biopharma Holdings, Inc. filed its quarterly report on Form 10-Q for the period ended November 5, 2026, accompanied by the CEO's Sarbanes-Oxley Section 302 certification.

Xeris Biopharma reported Q3 2026 total revenue of $107.2 million, up 44% year-over-year, driven by Recorlev net revenue growth of 93%. The company raised full-year 2026 total revenue guidance to $395-$405 million and increased its 2030 revenue outlook to more than $1 billion from approximately $750 million.

Xeris Biopharma Holdings appointed Menassie M. Taddese to its Board of Directors effective November 2, 2026, and he will also serve on the Board's Audit Committee.

A Schedule 13G/A amendment was filed regarding Xeris Biopharma Holdings, Inc. (XERS), indicating a change in a passive institutional holder's ownership position.

Xeris Biopharma Holdings, Inc. filed a Form 8-K with the SEC on October 14, 2026, reporting an event dated October 13, 2026. The filing contains only cover page and XBRL taxonomy information, with no substantive disclosure of a material event.

Xeris Biopharma provided an update on its XP-8121 program for hypothyroidism, including plans to initiate a Phase 3 trial by year-end 2026 and target potential FDA approval and commercial launch in 2030, with estimated peak revenue potential of $1-3 billion.